| Similar Articles |
|---|
 |
Chemistry World
April 1, 2015
Sanjay Kumar |
Sun Pharma snares Ranbaxy in $4bn deal Sun Pharma is now the fifth largest generics drug company in the world.   |
Chemistry World
April 22, 2015
Phillip Broadwith |
Daiichi Sankyo steps out after Sun-Ranbaxy merger Japanese firm Daiichi Sankyo has sold off its entire stake in India's Sun Pharmaceuticals, following Sun's takeover of Indian rival Ranbaxy, in which Daiichi was the controlling shareholder. |
Chemistry World
November 21, 2014
Rebecca Trager |
Ranbaxy sues over withdrawn US approvals Ranbaxy -- India's largest generics manufacturer -- has sued the US Food and Drug Administration after the agency withdrew tentative approval for the company to sell generic versions of two blockbuster drugs |
Chemistry World
September 18, 2008
James Mitchell Crow |
Ranbaxy hit by US drug ban The US Food and Drug Administration (FDA) has banned the import of more than 30 drugs made by Ranbaxy, India's largest drugmaker. |
Chemistry World
May 7, 2014
Phillip Broadwith |
Insider trading allegations stall Sun -- Ranbaxy deal The merger deal that would create India's largest pharmaceutical company has been stalled by accusations of insider trading of shares in the lead-up to the takeover announcement. |
Chemistry World
May 23, 2013
Phillip Broadwith |
$500m fine over generics fraud for Ranbaxy A long-running investigation by the US Department of Justice and Food and Drug Administration has ended with a $500 million fine for generic drugmaker Ranbaxy. |
The Motley Fool
September 18, 2008
Brian Orelli |
Ranbaxy's Troubles Won't Help Competitors The FDA will block the importing of more than 30 drugs and ingredients until Ranbaxy's problems at two Indian manufacturing plants are resolved. |
Chemistry World
August 21, 2015
Sa njay Kumar |
Indian pharma under increased regulatory scrutiny A Europe-wide ban on hundreds of generic pharmaceutical formulations tested by Indian contract research firm GVK Biosciences comes into force today. |
Chemistry World
July 16, 2015
Rebecca Trager |
US import ban imposed on Indian pharma firm The US Food and Drug Administration has prohibited India's Emcure Pharmaceuticals from importing drugs manufactured at its Maharashtra-based facility into the US owing to concerns over its manufacturing practices. |
Chemistry World
June 13, 2008
Sarah Houlton |
Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses. |
Chemistry World
July 28, 2008
Rebecca Trager |
Ranbaxy troubles place FDA under fire Indian drug firm Ranbaxy is facing scrutiny by American federal agencies and lawmakers over allegations that the company falsified scientific evidence to gain US approval for its products. |
Chemistry World
January 27, 2014
Phillip Broadwith |
US blocks imports from fourth Ranbaxy plant The US Food and Drug Administration has banned Indian drugmaker Ranbaxy from importing active pharmaceutical ingredients produced at its plant at Toansa, India, into the US. |
BusinessWeek
February 27, 2006
Einhorn & Kripalani |
In India, Selling Generics Used To Be So Easy Suddenly, Indian drugmakers Dr. Reddy's and Ranbaxy have a host of copycat rivals. |
Chemistry World
February 16, 2015
Phillip Broadwith |
Teva wins generic esomeprazole race The copycat version will be marketed by Ivax Pharmaceuticals, a subsidiary of Israeli generic behemoth Teva. |
BusinessWeek
July 14, 2003
Einhorn & Kripalani |
In India a Little Lab Work and Lots of Lawyers Ranbaxy, a maker of generic drugs, must win lawsuits to grow |
Chemistry World
October 23, 2013
Sarah Houlton |
Pharma manufacturing woes dog industry Many problems arise from quality control failures, according to Nicholson Price from Harvard Law School's Petrie-Flom center for health law policy, biotechnology and bioethics, this is not the only problem -- regulatory constraints can prevent process improvements being made. |
Chemistry World
May 3, 2012
Akshat Rathi |
Ranbaxy launches new anti-malarial Synriam It is the first recently developed antimalarial that is not based on artemisinin, one of the most effective treatments for malaria, which has begun to suffer from problems with resistance in recent years. |
The Motley Fool
February 26, 2009
Brian Orelli |
Ranbaxy Spoils It for Everyone The Food and Drug Administration claims that generic-drug maker Ranbaxy falsified data that it submitted to the agency. Other innocent drug companies may suffer from guilt by association. |
BusinessWeek
April 18, 2005
Manjeet Kripalani |
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India. |
Chemistry World
May 23, 2012
Andy Extance |
Drug watchdogs mark out global territory The US Food and Drug Administration has published plans to ensure that American citizens continue to enjoy access to safe drugs, even as the regulatory pressures of globalization grow. |
Chemistry World
October 17, 2014
Dinsa Sachan |
Indian manufacturers hit back over quality claims The Indian pharmaceutical industry has asked its government to sue authors of a study published by the US National Bureau of Economic Research in early September. |
Pharmaceutical Executive
September 1, 2008
Jill Wechsler |
Foreign Affairs FDA missteps and global outsourcing are drawing Congressional scrutiny and prompting new oversight approaches. |
BusinessWeek
October 10, 2005
Manjeet Kripalani |
India: A Quiet Shopping Spree So far, foreign companies being bought by Indian players are small - but that's likely to change |
The Motley Fool
May 13, 2008
Brian Orelli |
Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company. |
Pharmaceutical Executive
November 1, 2008
Patrick Clinton |
Over There Is it the FDA's responsibility to be in charge of inspections at foreign pharmaceutical plants? |
Pharmaceutical Executive
January 1, 2009
Jill Wechsler |
FDA Turnaround Time Will more resources and new leadership fix FDA, or is a major overhaul in order? |
The Motley Fool
September 30, 2008
Brian Lawler |
No Approval for You ... Yet The FDA makes Eli Lilly wait for word on a lead drug. |
The Motley Fool
July 22, 2008
Brian Orelli |
The Growth Doctor Is In Dr. Reddy's grows the top line, but it still has some work to do. |
The Motley Fool
December 19, 2005
Stephen D. Simpson |
Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma. |
Pharmaceutical Executive
October 1, 2011
Amrita Ghaswalla |
Changing the Dialogue No industry leader is more closely associated with the goal of seeding the globe with low-cost generics than Mumbai-based Cipla Chairman Y.K. Hamied. |
Chemistry World
May 26, 2015
Phillip Broadwith |
Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt. |
Chemistry World
March 17, 2014
Phillip Broadwith |
US focuses pharma supply chain scrutiny The US Food and Drug Administration has named 13 companies that will be allowed to import drug products into the US with reduced scrutiny. |
BusinessWeek
January 12, 2004
Manjeet Kripalani |
India: Big Pharma's New Promised Land? Drugmakers are heeding the siren call of its well-trained, cheap chemists. |
Pharmaceutical Executive
July 10, 2014
Ben Comer |
FDA Spread Thinly Abroad Is FDA capable of sufficiently overseeing global drug imports? |
Pharmaceutical Executive
April 1, 2012
Jill Wechsler |
Shortages and Sunshine Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors. |
Chemistry World
August 20, 2012 |
Generic Actos Approved Three generics manufacturers - Mylan, Ranbaxy and Teva - have won US marketing approval for their generic versions of Actos diabetes tablets. |
JavaWorld
May 2000
Brian Sullivan |
Sun dealt another blow in Java dispute with Microsoft In a ruling issued late Monday, the US District Court judge who is overseeing a pair of lawsuits that the two companies filed against each other dismissed Sun's claim that Microsoft had infringed on Sun's Java-related copyrights. |
The Motley Fool
July 26, 2005
Melanie Hollands |
Sun Still Setting Sun's deal with StorageTek isn't the savior that the company and some investors may think. |
InternetNews
July 22, 2010 |
Oracle Looks to Calm Sun Customer Concerns A Garter report found that Sun customers aren't happy with the flow of information from the company's new owner. Now Oracle is moving to calm frustrated Sun users. |
Pharmaceutical Executive
November 1, 2011
Jill Wechsler |
The Drug Shortages Struggle Clamor for critical therapies prompts probes of prices, production practices. |
Pharmaceutical Executive
August 1, 2012
Jill Wechsler |
Fleshing Out FDASIA Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation. In late June leading legislators reached across party lines to quickly approve the Food and Drug Administration Safety and Innovation Act. |
The Motley Fool
July 28, 2005
Tom Taulli |
Is Sun Getting Eclipsed? Maybe the best strategy for Sun is just to give money back to its shareholders. |
InternetNews
February 17, 2009
Paul Shread |
Sun's Encryption Keys Going Open Source Just days after seven IT vendors proposed an encryption key management standard, Sun is open sourcing its own key management technology. |
Pharmaceutical Executive
January 1, 2007
Jill Wechsler |
Washington Report: A Full Plate It's going to be a busy year in Washington for the pharmaceutical industry. Drug safety, unapproved uses, e-data requirements, and a shift to personalized medicine are just a few of the hot issues on tap for 2007. |
Pharmaceutical Executive
July 1, 2014
Jill Wechsler |
Pre-emption and States' Rights Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. |
Chemistry World
January 6, 2015
Sarah Houlton |
Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion. |
The Motley Fool
January 14, 2005
Ben McClure |
Is Buying Sun a Bright Idea? Whether you love or hate Sun Microsystems depends on your investment style. |
JavaWorld
January 2001
James Niccolai |
Sun, Microsoft settle Java lawsuit Microsoft has agreed to pay Sun Microsystems $20 million as part of an agreement to settle a bitter, 3-year legal battle over its use of Sun's Java programming language... |
Pharmaceutical Executive
January 1, 2007 |
Thoughtleader: Peter Pitts. DrugWonks.com Here, the chief voice of a blog hosted by the non-profit Center for Medicine in the Public Interest urges pharma to continuously plug its positions and get politics out of science, and offers some perspective on important regulatory reforms facing the FDA. |
Pharmaceutical Executive
July 3, 2007 |
Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work. |
